IGF1R and neoplasm: Genetic or pharmacologic dampening of IGF1R signaling restores drug response and, in vivo, surufatinib + linsitinib effectively restrains tumor growth; conversely, IGF1R overexpression or Y1165/1166-activating mutants blunt surufatinib efficacy.